Brief: Visiomed Extends Partnership With LiClear Biotech On COVID-19 Tests
Oct 28 (Reuters) - VISIOMED GROUP SA ALVMG.PA :
* NEW DISTRIBUTION AGREEMENT CLAUSE AND FIRST ORDERS FOR
COVID-19
RAPID DIAGNOSTIC ANTIGEN TESTS
* AGREEMENT SIGNED WITH CHINESE LABORATORY LICLEAR BIOTECH
IN H1
2020, EXTENDED TO COVID-19 RAPID DIAGNOSTIC ANTIGEN TESTS
* FIRST DELIVERIES SCHEDULED FOR EARLY NOVEMBER
Source text for Eikon: ID:nACT65836
Further company coverage: ALVMG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Klea Holding SA
See all newsSmart Salem Centers Volume Growth At +31% In Q1
Brief: Visiomed Posts FY Consolidated Net Loss Of 1.1 Million Euros
Brief: Visiomed Appoints Clément Pacaud As Group CEO
Brief: Visiomed Announces 60% Growth In Performed Tests During Q3
Brief: Visiomed Group Received Favourable Order From President Of Paris Commercial Court